William Blair Upgrades Neumora Therapeutics to Outperform on Promising Alzheimer's Agitation Data

William Blair analyst upgrades Neumora Therapeutics to Outperform after strong early data for its Alzheimer's agitation drug NMRA-511, seeing big potential in a huge market.